Has Joshua Groves, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,148 in general payments to Joshua Groves, MD across 148 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joshua Groves, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joshua Groves, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joshua Groves, MD

Plastic and Reconstructive Surgery · Macon, GANPI 1528281276

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,599 of the $5,148 with a category attached, or 69.9%. 28 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2019 at $2,280 and has fallen 73.2% since, to $611 in 2025.

$5,148in general payments, 2019–2025

Across 148 payments — averaging $34.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
KCI USA, Inc.$800
Musculoskeletal Transplant Foundation Inc.$667
Mentor Worldwide LLC$532
Integra Lifesciences Corporation$371
Merz North America, Inc.$325
plus $1K from 22 others

What the payments were for

Consulting fees$80016%
Travel & lodging$4088%
Food & beverage$3,59970%
Education$160%
Other$3266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	63	$1,281
KCI USA, Inc.	1	$800
Musculoskeletal Transplant Foundation Inc.	9	$667
Mentor Worldwide LLC	21	$532
Integra Lifesciences Corporation	3	$371
Merz North America, Inc.	4	$325
Baxter Healthcare	4	$191
Galderma Laboratories, L.p.	7	$114
Johnson & Johnson	4	$111
Davol Inc.	2	$95
Kerecis Limited	3	$91
Regeneron Healthcare Solutions, Inc.	4	$81
Polarityte, Inc.	2	$62
Polynovo North America LLC	2	$49
Motiva USA, LLC	2	$49
TELA Bio, Inc.	2	$40
Pacira Pharmaceuticals Incorporated	2	$40
Zimmer Biomet	1	$30
Sientra, Inc.	1	$29
Kls-martin L.p.	2	$28
BD	1	$26
Aroa Biosurgery Incorporated	2	$23
Avanos Medical	1	$22
Sanara Medtech Inc.	1	$21
Heron Therapeutics, Inc.	1	$20
Lifenet Health	1	$19
Apyx Medical Corporation	1	$16
Convatec Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,148 in reported general payments places this provider in the 70th percentile of 83 plastic and reconstructive surgery providers in Georgia.

See all plastic and reconstructive surgery providers in Georgia →

Medicare billing

Part B allowed, 2024

$46,438

Medicare patients

Services billed

206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron OdtOndansetron	27	$332
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	38	$246
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	16	$194
Scopolamine	12	$168

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Macon

Christopher McLendonMacon$4K
Taylor McLendonMacon$4K
Rajiv SoodAugusta$502K
Carmen KavaliAtlanta$233K
Randal RuddermanAlpharetta$207K
James NamnoumAtlanta$97K
Michael MirzabeigiAtlanta$71K
Katherine SantosaAtlanta$65K
Marc YuneRoswell$64K
Asaf YalifAlpharetta$43K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →